Logo image of OLMA

OLEMA PHARMACEUTICALS INC (OLMA) Stock Fundamental Analysis

NASDAQ:OLMA - Nasdaq - US68062P1066 - Common Stock - Currency: USD

4.13  +0.03 (+0.73%)

After market: 4.04 -0.09 (-2.18%)

Fundamental Rating

3

OLMA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. While OLMA has a great health rating, there are worries on its profitability. OLMA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OLMA has reported negative net income.
In the past year OLMA has reported a negative cash flow from operations.
OLMA had negative earnings in each of the past 5 years.
In the past 5 years OLMA always reported negative operating cash flow.
OLMA Yearly Net Income VS EBIT VS OCF VS FCFOLMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

The Return On Assets of OLMA (-31.47%) is better than 64.63% of its industry peers.
With a decent Return On Equity value of -33.61%, OLMA is doing good in the industry, outperforming 74.51% of the companies in the same industry.
Industry RankSector Rank
ROA -31.47%
ROE -33.61%
ROIC N/A
ROA(3y)-37.4%
ROA(5y)-28.65%
ROE(3y)-40.93%
ROE(5y)-30.97%
ROIC(3y)N/A
ROIC(5y)N/A
OLMA Yearly ROA, ROE, ROICOLMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

OLMA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OLMA Yearly Profit, Operating, Gross MarginsOLMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for OLMA has been increased compared to 1 year ago.
OLMA has more shares outstanding than it did 5 years ago.
OLMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OLMA Yearly Shares OutstandingOLMA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
OLMA Yearly Total Debt VS Total AssetsOLMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 4.82 indicates that OLMA is not in any danger for bankruptcy at the moment.
OLMA has a Altman-Z score of 4.82. This is in the better half of the industry: OLMA outperforms 78.10% of its industry peers.
OLMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.82
ROIC/WACCN/A
WACCN/A
OLMA Yearly LT Debt VS Equity VS FCFOLMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

OLMA has a Current Ratio of 15.22. This indicates that OLMA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of OLMA (15.22) is better than 88.33% of its industry peers.
OLMA has a Quick Ratio of 15.22. This indicates that OLMA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 15.22, OLMA belongs to the top of the industry, outperforming 88.33% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.22
Quick Ratio 15.22
OLMA Yearly Current Assets VS Current LiabilitesOLMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 0.50% over the past year.
EPS 1Y (TTM)0.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -2.15% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.32%
EPS Next 2Y5.35%
EPS Next 3Y2.69%
EPS Next 5Y-2.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OLMA Yearly Revenue VS EstimatesOLMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
OLMA Yearly EPS VS EstimatesOLMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OLMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OLMA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OLMA Price Earnings VS Forward Price EarningsOLMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OLMA Per share dataOLMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.35%
EPS Next 3Y2.69%

More info and screens

0

5. Dividend

5.1 Amount

OLMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OLEMA PHARMACEUTICALS INC

NASDAQ:OLMA (6/20/2025, 8:00:02 PM)

After market: 4.04 -0.09 (-2.18%)

4.13

+0.03 (+0.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-04 2025-08-04
Inst Owners98.67%
Inst Owner Change-7.23%
Ins Owners4.18%
Ins Owner Change-6.93%
Market Cap282.57M
Analysts85.71
Price Target24.65 (496.85%)
Short Float %9.61%
Short Ratio7.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.34%
Min EPS beat(2)21.88%
Max EPS beat(2)30.8%
EPS beat(4)3
Avg EPS beat(4)13.83%
Min EPS beat(4)-1.8%
Max EPS beat(4)30.8%
EPS beat(8)6
Avg EPS beat(8)12.09%
EPS beat(12)8
Avg EPS beat(12)8.13%
EPS beat(16)10
Avg EPS beat(16)5.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.46%
PT rev (3m)-17.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)35.67%
EPS NY rev (1m)14.26%
EPS NY rev (3m)36.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-2.01
EYN/A
EPS(NY)-1.97
Fwd EYN/A
FCF(TTM)-1.82
FCFYN/A
OCF(TTM)-1.82
OCFYN/A
SpS0
BVpS5.6
TBVpS5.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.47%
ROE -33.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.4%
ROA(5y)-28.65%
ROE(3y)-40.93%
ROE(5y)-30.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.22
Quick Ratio 15.22
Altman-Z 4.82
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)46.82%
Cap/Depr(5y)345.59%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
EPS Next Y21.32%
EPS Next 2Y5.35%
EPS Next 3Y2.69%
EPS Next 5Y-2.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.26%
EBIT Next 3Y-13.34%
EBIT Next 5YN/A
FCF growth 1Y-47.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.63%
OCF growth 3YN/A
OCF growth 5YN/A